PDB reference: human muscle phosphofructokinase, 4omt
Introduction
The main regulator of glycolysis, 6-phosphofructokinase (EC 2.7.1.11; Pfk), catalyzes the Mg-ATP-dependent formation of fructose 1,6bisphosphate from fructose 6-phosphate in prokaryotic and eukaryotic cells. Pfk is regulated and fine-tuned by a wide range of effectors (Sols, 1981; Tejwani, 1978; Schö neberg et al., 2013) . Physiologically most relevant are AMP and fructose 2,6-bisphosphate (F-2,6-BP; Reinhart & Lardy, 1980; Zancan et al., 2007) as activators as well as ATP and citrate as inhibitors (Zancan et al., 2008; Usenik & Legiša, 2010; Schö neberg et al., 2013) . Recently, it was demonstrated that acyl-CoA modulates Pfk activity through both covalent and noncovalent interactions (Jenkins et al., 2011) . Furthermore, binding of Pfk to intracellular proteins such as calmodulin (Marinho-Carvalho et al., 2006) , actin (Liou & Anderson, 1980) , microtubules (Vé rtessy et al., 1997) and caveolin 1 (Vallejo & Hardin, 2005) modulates the activity, oligomeric equilibrium and localization of Pfk within the cell. Moreover, the equilibrium between monomer, dimers, tetramers and higher oligomers affects Pfk activity (Trujillo & Deal, 1977; Luther et al., 1983) . Mutations in the muscle Pfk gene can lead to type VII glycogen storage disease (Tarui disease; Toscano & Musumeci, 2007) . More recently, post-translational modifications in terms of truncated C-termini were found in tumorigenic cell lines (Smerc et al., 2011) . A further post-translational modification of Pfk, namely O-GlcNacylation, represents a mechanism for the regulation of metabolic pathways in cancer cells, suggesting a possible strategy to combat cancer (Yi et al., 2012) .
The enzyme from Trypanosoma brucei was the first eukaryotic representative to be structurally characterized. However, it is more similar to the bacterial diphosphate-dependent Pfk enzymes (Martinez-Oyanedel et al., 2007; McNae et al., 2009) . Despite early reports of the crystallization of rabbit muscle Pfk (rmPfk; Parmeggiani et al., 1966) , the first structures of characteristic eukaryotic ATPdependent Pfk became available only a few years ago via the Pfk structures from the yeasts Pichia pastoris (Strä ter et al., 2011) in the T-state and Saccharomyces cerevisiae in the R-state (Banaszak et al., 2011) as well as that of rmPfk (Banaszak et al., 2011) . The crystals of rmPfk contain a homodimer which probably models one half of the physiological tetramer. Structural information on the allosteric switch of bacterial Pfk is based mainly on the two Bacillus stearothermophilus Pfk structures in the active state (PDB entry 4pfk) and in the T-state (PDB entry 6pfk) (Evans et al., 1981; Schirmer & Evans, 1990) .
In this study, a preliminary crystallographic analysis of wild-type human muscle Pfk (hmPfk) is presented. This constitutes an important step towards our goal of characterizing the allosteric states, the binding of regulators and the conformational switch of human Pfk isozymes.
Materials and methods

Macromolecule production
Wild-type human muscle Pfk cDNA (UniProtKB P08237-1) was cloned into the plasmid pJJH71 (Raben et al., 1995;  kindly provided by Professor Dr Jü rgen J. Heinisch, University of Osnabrü ck). hmPfk was expressed in S. cerevisiae strain HD114-8D carrying a deletion in both yeast Pfk genes (Raben et al., 1995) . The protein was purified as described previously in Brü ser et al. (2012) . Macromoleculeproduction information is given in Table 1 .
Crystallization
A buffer exchange was performed prior to crystallization using PD10 desalting columns (GE Healthcare) and sample buffer ( Table 2 ). The eluted protein was concentrated to 6-11 mg ml À1 by ultrafiltration (Vivaspin 6, Sartorius). Initial screening for crystallization conditions was performed with commercially available crystallization screens (from Hampton Research and Jena Bioscience) at 292 K using the sitting-drop vapour-diffusion technique in three-drop 96-well plates (Greiner). The volume of the reservoir solution was 90 ml. Equal volumes (0.2 ml) of reservoir and protein solution were dispensed using a MicroSys eight-channel dispensing system (Zinsser Analytic). Optimizations of the initial hits were performed by changing the pH value and the precipitant and protein concentrations, as well as the temperature, using the hanging-drop vapour-diffusion method. The same volumes of protein and reservoir solution (1 ml) were mixed and equilibrated against 500 ml reservoir solution in 24-well trays (Nelipak). Crystals of hexagonal shape ( Fig. 1a ) grew in 0.6 M LiNO 3 . Crystals appeared within a few days and usually reached their final size within 5 days. For further optimization of crystal quality, microbatch-under-oil crystallization techniques, crystallization in agarose gel, additive screens (including Silver Bullets and Silver Bullets Bio, Hampton Research), in situ proteolysis, different seeding techniques and cross-linking were tested. The screening of cryoprotectants [glycerol, MPD, ethylene glycol (PEG) 200, PEG 400, glucose, fructose, sucrose and fructose 6-phosphate] revealed PEG 200 to be the most suitable. Before data collection, crystals were cryoprotected by the stepwise addition of 10, 15, 20 and 25% PEG 200 to the reservoir buffer and were cooled in liquid nitrogen.
Data collection and processing
Data collection was performed at HZB (BESSY II, beamline 14.1). Data processing was performed with XDS (Kabsch, 2010 Table 1 Macromolecule-production information.
Source organism
Homo sapiens DNA source hmPfk cDNA Expression vector pJJH71PFK (Raben et al., 1995) 
Expression host
S. cerevisiae strain HD114-8D Complete amino-acid sequence of the construct produced UniProtKB P08237-1: LESS was used to determine the Laue group (Evans, 2006) , and the reflections were scaled and merged with AIMLESS (Evans, 2006) . Cell-content analysis with MATTHEWS_COEF indicated the presence of one monomer per asymmetric unit with 79.5% solvent content (Matthews, 1968; Kantardjieff & Rupp, 2003) .
Structure solution and refinement
The structure of rmPfk (PDB entry 3o8n; Banaszak et al., 2011) modified by CHAINSAW (Stein, 2008) served as a search model for molecular replacement with Phaser (McCoy et al., 2007) . The MR solution with an LLG score of 616 and a TFZ score of 25.5 indicates a definite solution. After rigid-body refinement of the rmPfk structure with REFMAC5 (Murshudov et al., 2011) the R and R free factors improved to 40.2 and 45.0%, respectively. An hmPfk model was generated by exchange of the differing residues and modelling in the most probable conformer that did not generate close contacts. Furthermore, the N-and C-termini were truncated (residues 8-755) based on the visible electron density. For further refinement, residues 8-394 and 395-755 were refined as independent rigid bodies. These regions correspond to the homologous N-terminal and C-terminal halves of eukaryotic Pfk that are related to a bacterial Pfk monomer. This resulted in R and R free values of 38.7 and 41.3%, respectively. Finally, a group B-factor refinement (one B value per residue) was performed with phenix.refine (Adams et al., 2010) . Phenix.autobuild was used for the calculation of an iterative composite OMIT map (Terwilliger, Grosse-Kunstleve, Afonine, Moriarty, . Crystal packing and electron-density maps of human muscle Pfk. The crystal packing (transparent grey cartoon) is viewed along the 6 2 symmetry axis (a) and the twofold symmetry axis (b). One hmPfk monomer is shown in blue and the second subunit of the dimer is coloured orange. The diameter of the solvent channel along the 6 2 axis is approximately 84 Å . (c) 2F o À F c (blue) and F o À F c (green/red) maps after rigid-body and group B-factor refinement. (d) Iterative composite OMIT map (blue).
Coot was used to mutate the initial model in order to generate the hmPfk model (Emsley & Cowtan, 2004) . Molecular diagrams were drawn using PyMOL (Schrö dinger).
Results and discussion
The diffraction limit of the first crystals of hmPfk was 12 Å and could be optimized to 6 Å . However, the crystals tended to break easily during the cryocooling step. Many crystals had to be tested at synchrotron beamlines, since the crystal quality after cryocooling generally differed considerably. The best data set obtained from these crystals extended to $6.0 Å resolution (Table 3 ; Fig. 1b ). All trials to improve the diffraction properties of the crystals by seeding, in situ proteolysis or the use of additives were not successful. Diffraction tests at room temperature without the cryocooling step also resulted in weak diffraction to a low resolution of >8 Å . Determination of an optimal cryoprotectant and cooling the crystals did not improve the resolution beyond 6 Å .
To analyze the packing and quaternary structure of hmPfk in the crystals, we used the structure of one monomer of rabbit skeletal muscle Pfk (PDB entry 3o8n), which has a sequence identity of 96%, as the search model in molecular replacement. One monomer was found in the asymmetric unit, resulting in a loose packing with large solvent channels along the 6 2 screw axes (Fig. 2a) . The high solvent content of 79.5% probably contributes to the instability and weak diffraction properties of the nicely shaped hmPfk crystals (Fig. 1a) .
The N-and C-terminal halves of hmPfk were refined as independent rigid bodies based on the rmPfk model obtained at 3.2 Å resolution, followed by a group B-factor refinement, resulting in R and R free values of 23.9 and 27.4%, respectively. Refinement statistics are given in Table 4 . Because of the limited resolution of the crystals, further refinement was not carried out. Fig. 2 shows the normal and iterative composite OMIT electron-density maps, which confirm the correctness of the MR solution. As in the structure of rmPfk, the physiological tetramer (Tsai & Kemp, 1973; Arechaga et al., 2010) of hmPfk is dissociated into a dimer (Fig. 3) . Although rmPfk (residues 1-762) was crystallized in a different hexagonal crystal form (space group P6 1 22, unit-cell parameters a = 163.3, c = 356.9 Å ), the dimers are very similar (Fig. 3b) . Superposition with the structures of the yeast Pfks from Pichia pastoris (Strä ter et al., 2011; PDB entry 3opy; Fig. 3a ) and Saccharomyces cerevisiae Pfk (Banaszak et al., 2011; PDB entry 3o8o) reveals that these dimer structures are part of the yeast Pfk tetramers and thus most likely model at least part of the physiological tetramer of mammalian Pfk. Interestingly, the dimers with the smaller protein-protein interface across the putative tetramerization interface are maintained, whereas the closer interacting dimers corresponding to the bacterial homotetramers are dissociated (Fig. 3a) . This dissociation could be driven by the protonation of His199 present at the tetramerization interface, which in its unprotonated form presumably interacts with the backbone NH group of the conserved residue Gly24 or Gly25. Therefore, we assume that the dissociation of hmPfk into dimers occurs owing to the low pH of the crystallization buffer, as previously suggested based on the rmPfk structure (Banaszak et al., 2011) . In summary, hmPfk and rmPfk have been crystallized as a dimer representing half of the physiologically active homotetramer. This dimer has now been observed in two independent crystal forms in different packing environments (not shown) and for two different (albeit highly identical) enzymes, indicating that this dimer structure may be the inactive dimer of mammalian Pfk discussed in previous studies to be involved in the regulation of Pfk activity (Mayr, 1984; Buschmeier et al., 1987; Marinho-Carvalho et al., 2006 ). These dimer structures may also help in the design of constructs for the crystallization of physiologically active homotetrameric mammalian Pfk.
